Relief Therapeutics Holding AG (RLFTF)

[ratna1]

Elk,we are being gifted with a billion $ promotional campaign compliments of NHI and FDA with this direct comaprison of AVIPTADIL vs. REMDESIVIR as I pointed out earlier:

When I first read the news of the international clincial study of the direct comparison of AVIPTADIL with REMDESIVIR it gave me goose bumps all over as I recognized the tremendous significance that will catapult AVIPTADIL into the TOP TEN of COVID19 meds as soon as the trial will officially be announced by the NIH!

( Even so it also pushes the timeline for massive gains in shareprice back for another 4-6 more months...)
(see below: II.a.:)

As REMDESIVIR is without proven statistical significance EXCEPT highly toxic - even deadly - side effects it’s use is basically nothing more than a Hail Mary application signaling total capitulation by emergency room and intensive care docs because they have NOTHING else as a therapeutic intervention on hand with patients dying on ventilation and ECMO!!

Obviously it was Team Orange with it's cozy interdependent relationship with campaign donors from GILEAD and it's intimate closed doors hugging sessions with their lobbyists that led to the application for EUA being granted for REMDESIVIR in just ONE (1!) day without clinical data to support it!
Talking 'bout armlength negotiations....
(see below: I.:)

What this really means for me is that Janet Woodcock and the other professionals at the FDA had had enough of the cronies of Trump being pushed ahead of them and being allowed to do damage for personal profits ( just like that Postmaster trying to dismantle the Postal Service even so he holds shares big time in direct competitors of the USPS).
Since it would come across really bad to call "Foul" and raise accusations of corrupt dealings within the agency it is easier and far more effective to directly compare REMDESIVIR with AVIPTADIL and it's already proven superior efficacy :
(see below:II.b.)
.
It is going to blow REMDESIVIR with it's potentially lethal long term side effects right out of the water without raising a direct accusation.
The results will fall back on the feet of those responsible for this reckless EUA simply due to power of gravity
Our problem is that timelapse until this space debris is pulled back to earth and the pubication of the results...
The outstanding positive is that this trial will take place in 8 countries across 3 continents thus basically broadcasting the results to ALL the doctors around the world using REMDESIVIR out of desperation!


In the long run this means that we will have a billion dollar marketing campaign for free because every practicing emergency and intensive care doctor will be informed about the failure of REMDESIVIR at once !
I presume this will be one of the most watched clinical trials world wide!
(And not only by doctors desperate for an effective therapeutic but also M&A specialists

What I am fairly shocked with is the share price decline instead of a break out?!?!

I cannot comprehend how people have missed this game changing news?
With this overwhelming developments we ought to be up above 1,00 SFr respectively 1,1US$ already...

Maybe it is the updated valuation report that RLF management commissioned …
we don't need a Short hitpiece as long as management employs these bashers!

Question is :
how to survive this long with our investment whilst NASDAQ hitting All Time Highs all the time...


Best Regards to All!

References:

I.:

Remdesivir starts 2 Phase 3 Clinical Trials on 26/2/20
Remdesivir Results 29/4/20
FDA Emergency Use Authorization 1/ 5/20

Results Of 2483 consecutive admissions, 342 individuals received remdesivir, 184 of whom also received corticosteroids and 158 of whom received remdesivir alone. For these 342 patients, the median age was 60 years (interquartile range, 46-69 years), 189 (55.3%) were men, and 276 (80.7%) self-identified as non-White race/ethnicity.
Remdesivir recipients had a shorter time to clinical improvement than matched controls without remdesivir treatment (median, 5.0 days [interquartile range, 4.0-8.0 days] vs 7.0 days [interquartile range, 4.0-10.0 days]; adjusted hazard ratio, 1.47 [95% CI, 1.22-1.79]).

The addition of corticosteroids to remdesivir was not associated with a reduced hazard of death at 28 days (adjusted hazard ratio, 1.94; 95% CI, 0.67-5.57).

II.a.:

https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-has-been-selected-for-inclusion-in-nih-sponsored-global-clinical-trial-to-include-aviptadil-and-remdesivir-301262506.html